People

Becky Kaufman specializes in the development, procurement and commercial exploitation of patent rights. A partner in our Intellectual Property Counseling practice, Becky counsels public and private companies, investors and research organizations, primarily in the life sciences, industrial biotechnology and chemical industries.

Becky regularly structures and negotiates a wide range of IP-based commercial and strategic transactions, including licensing and collaboration deals as well as research and development, material transfer, manufacturing, supply and distribution agreements. She also represents clients in U.S. and international patent procurement, adversarial proceedings and transactional due diligence, including both established and emerging companies. Becky brings pragmatic business experience and solid technical credentials to her practice. 

Prior to joining the firm, Becky was a principal with Cordova Ventures, an early stage venture capital fund. She also previously worked for the Georgia Institute of Technology's Advanced Technology Development Center, recognized as one of nation's top technology incubators. In both roles, Becky counseled start-ups on a variety of business and intellectual property issues. She is active in the life sciences community and has served in leadership roles with several state and regional organizations. 

Becky has been recognized as an IP Star by Managing Intellectual Property from 2013 through 2019. Intellectual Property Asset Management describes her commercial IP credentials as "some of the best in the business." 

Full Bio

Credentials

J.D., University of Pittsburgh

B.S., Wake Forest University

Georgia

Strategy 300: The World's Leading IP Strategists


Intellectual Asset Management, 2016, 2015

Patent 1000: The World's Leading Patent Professionals


Intellectual Asset Management, 2016, 2015

Icon close

Close

Recognition

Strategy 300: The World's Leading IP Strategists


Intellectual Asset Management, 2016, 2015

Patent 1000: The World's Leading Patent Professionals


Intellectual Asset Management, 2016, 2015

Matters

Advised Arbor Pharmaceuticals, Inc., as IP counsel in connection with its $476 million acquisition of XenoPort, Inc.

Represents Revivicor, Inc. (a subsidiary of United Therapeutics) in client counseling and development of its patent portfolio relating to genetically modified porcine for xenotransplanation.

Represents Nitto Denko Corporation in U.S. and international prosecution of its enhanced transdermal drug-delivery portfolio.

See more
Icon close

Close

Matters

Advised Arbor Pharmaceuticals, Inc., as IP counsel in connection with its $476 million acquisition of XenoPort, Inc.

Represents Revivicor, Inc. (a subsidiary of United Therapeutics) in client counseling and development of its patent portfolio relating to genetically modified porcine for xenotransplanation.

Represents Nitto Denko Corporation in U.S. and international prosecution of its enhanced transdermal drug-delivery portfolio.

Represents The Coca-Cola Company in development of its patent portfolio relating to sweetness enhancers, natural sweeteners and other flavor ingredients.

Represents Emory University in prosecution of its patent portfolio relating to 2'-Fluoro-nucleosides for treatment of viral diseases.

Represented Arbor Pharmaceuticals, Inc. as IP counsel in connection with KKR's acquisition of a minority interest that valued the company at greater than $1 billion.

Represents Kemira in connection with development of its patent portfolio relating to chemical products for use in oil, gas and mining.

Represents Duke University in U.S. and international prosecution of its patent portfolio relating to nucleic acid aptamers targeting therapeutically important proteins, including coagulation proteins.

Represents The Coca-Cola Company in development of its patent portfolio relating to bio-based plastics, including bio-polyethylene terephthalate, or PET, and polyethylene furanoate, or PEF, including PlantBottle.

Represented Regado Biosciences (Tobira Therapeutics) as IP counsel in multiple transactions, including venture capital financings, geographical-based licensing and its initial public offering.

Represented The Coca-Cola Company in negotiating and drafting licensing, development and commercialization agreements relating to novel sweeteners and bio-plastics.

Represented a privately held ophthalmology company in connection with a partial acquisition by a multi-national ophthalmology company.

Represented Nivalis Therapeutics, Inc., as IP counsel in connection with its initial public offering.

Represents Aceras Bio, a healthcare investment firm, in due diligence directed to formation and funding of life sciences companies.

Represents GeoVax, Inc., in client counseling and development of its patent portfolio relating to vaccines for HIV and other viral disorders.

Represented EndoChoice, a platform GI company, as IP counsel in connection with its initial public offering.

Represented a multinational conglomerate in monetization of a patent portfolio directed to mass spectrometric imaging by MALDI-TOF.

Insights

View all

Matters

Advised Arbor Pharmaceuticals, Inc., as IP counsel in connection with its $476 million acquisition of XenoPort, Inc.

Represents Revivicor, Inc. (a subsidiary of United Therapeutics) in client counseling and development of its patent portfolio relating to genetically modified porcine for xenotransplanation.

Represents Nitto Denko Corporation in U.S. and international prosecution of its enhanced transdermal drug-delivery portfolio.

See more
Icon close

Close

Matters

Advised Arbor Pharmaceuticals, Inc., as IP counsel in connection with its $476 million acquisition of XenoPort, Inc.

Represents Revivicor, Inc. (a subsidiary of United Therapeutics) in client counseling and development of its patent portfolio relating to genetically modified porcine for xenotransplanation.

Represents Nitto Denko Corporation in U.S. and international prosecution of its enhanced transdermal drug-delivery portfolio.

Represents The Coca-Cola Company in development of its patent portfolio relating to sweetness enhancers, natural sweeteners and other flavor ingredients.

Represents Emory University in prosecution of its patent portfolio relating to 2'-Fluoro-nucleosides for treatment of viral diseases.

Represented Arbor Pharmaceuticals, Inc. as IP counsel in connection with KKR's acquisition of a minority interest that valued the company at greater than $1 billion.

Represents Kemira in connection with development of its patent portfolio relating to chemical products for use in oil, gas and mining.

Represents Duke University in U.S. and international prosecution of its patent portfolio relating to nucleic acid aptamers targeting therapeutically important proteins, including coagulation proteins.

Represents The Coca-Cola Company in development of its patent portfolio relating to bio-based plastics, including bio-polyethylene terephthalate, or PET, and polyethylene furanoate, or PEF, including PlantBottle.

Represented Regado Biosciences (Tobira Therapeutics) as IP counsel in multiple transactions, including venture capital financings, geographical-based licensing and its initial public offering.

Represented The Coca-Cola Company in negotiating and drafting licensing, development and commercialization agreements relating to novel sweeteners and bio-plastics.

Represented a privately held ophthalmology company in connection with a partial acquisition by a multi-national ophthalmology company.

Represented Nivalis Therapeutics, Inc., as IP counsel in connection with its initial public offering.

Represents Aceras Bio, a healthcare investment firm, in due diligence directed to formation and funding of life sciences companies.

Represents GeoVax, Inc., in client counseling and development of its patent portfolio relating to vaccines for HIV and other viral disorders.

Represented EndoChoice, a platform GI company, as IP counsel in connection with its initial public offering.

Represented a multinational conglomerate in monetization of a patent portfolio directed to mass spectrometric imaging by MALDI-TOF.

Insights

View all

Credentials

J.D., University of Pittsburgh

B.S., Wake Forest University

Georgia

Strategy 300: The World's Leading IP Strategists


Intellectual Asset Management, 2016, 2015

Patent 1000: The World's Leading Patent Professionals


Intellectual Asset Management, 2016, 2015

Icon close

Close

Recognition

Strategy 300: The World's Leading IP Strategists


Intellectual Asset Management, 2016, 2015

Patent 1000: The World's Leading Patent Professionals


Intellectual Asset Management, 2016, 2015